Shares of Evotec AG (NASDAQ:EVTCY) have received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Zacks has also assigned Evotec AG an industry rank of 97 out of 265 based on the ratings given to related companies.
EVTCY has been the subject of several recent research reports. DZ Bank AG restated a “buy” rating on shares of Evotec AG in a research note on Monday, July 11th. Zacks Investment Research upgraded Evotec AG from a “hold” rating to a “strong-buy” rating and set a $11.00 price target for the company in a research note on Friday, August 12th.
Evotec AG (NASDAQ:EVTCY) opened at 10.9299 on Monday. Evotec AG has a 12-month low of $6.56 and a 12-month high of $10.96. The company has a 50-day moving average price of $9.94 and a 200 day moving average price of $8.60. The company has a market cap of $724.37 million and a PE ratio of 124.2034.
About Evotec AG
Evotec AG (Evotec) is a drug discovery and development company. The Company is engaged in providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors. The Company has two segments: EVT Execute and EVT Innovate. EVT Execute segment offers stand-alone or integrated drug discovery solutions for collaborator’s targets and programs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.